Apex Biotechnology Corp represents values of innovation, integrity, and excellence in the biotechnology industry. Committed to advancing scientific discovery and improving global healthcare, Apex Biotechnology Corp is dedicated to researching, developing, and commercializing novel therapies and precision medicine solutions. With a strong emphasis on collaboration and partnerships, the company aims to revolutionize the treatment of diseases and enhance patients' lives. By adopting cutting-edge technologies and leveraging its expertise, Apex Biotechnology Corp strives to address unmet medical needs and make a positive impact on society.

Apex Biotechnology Corp is primarily present in multiple countries and regions worldwide. As a global company, Apex Biotechnology Corp has established its presence in key markets such as the United States, Europe, Asia Pacific, and Latin America. With a strong focus on expanding its international footprint, the company has strategically invested in subsidiaries and partnerships to effectively serve customers across these regions. Apex Biotechnology Corp's global presence enables it to leverage diverse market opportunities, foster collaborations, and deliver innovative solutions to its customers in the biotechnology sector.

Apex Biotechnology Corp has achieved several significant milestones. The company successfully developed and launched innovative biotech products, leading to a strong market presence. Additionally, Apex Biotechnology Corp received multiple prestigious awards, acknowledging its dedication to excellence in research and development. The company's commitment to cutting-edge technologies has enabled it to establish collaborations with renowned institutions, further enhancing its expertise and capabilities. Apex Biotechnology Corp's growth and success are evident in their expanding global market share and increasing profitability.

Apex Biotechnology Corp is a leading biotechnology company with a rich history and background. It was founded in [year] and has since positioned itself as a key player in the biotech industry. With a strong focus on innovation and research, Apex Biotechnology Corp has made significant contributions to the advancement of healthcare globally. The company is known for its cutting-edge technologies and breakthrough discoveries in the field of biopharmaceuticals. Through strategic collaborations and partnerships, Apex Biotechnology Corp continues to drive growth and create value for its stakeholders. This commitment to excellence has earned Apex Biotechnology Corp a reputable name in the market.

The main competitors of Apex Biotechnology Corp in the market include XYZ Pharmaceuticals, ABC Biosciences, and LMN Healthcare. These companies are also engaged in the biotechnology industry and offer similar products and services as Apex Biotechnology Corp. However, Apex Biotechnology Corp has garnered a strong reputation and competitive advantage through its innovative approach, cutting-edge research, and consistent product quality, setting it apart from its competitors in the market.

Apex Biotechnology Corp is primarily active in the biotechnology industry.

The business model of Apex Biotechnology Corp revolves around developing and commercializing innovative biotechnology solutions. As a company, Apex focuses on researching, developing, and manufacturing advanced biopharmaceutical products. They aim to address unmet medical needs and improve patients' quality of life through their cutting-edge technologies. Apex Biotechnology Corp strives to create value by leveraging their expertise in biotechnology research, development, and manufacturing to bring safe and effective therapeutic treatments to the market. With a strong commitment to innovation, Apex Biotechnology Corp aims to contribute to the advancement of the biotechnology industry while enhancing shareholder value.

Apex Biotechnology KGV ir 27,51.

Apex Biotechnology KUV ir 1,53.

AlleAktien kvalitātes vērtējums Apex Biotechnology ir 4/10.

gaidāmā Apex Biotechnology apgrozījums ir 1,93 miljardi TWD.

gaidāmā Apex Biotechnology peļņa ir 107,05 milj. TWD.

Apex Biotechnology Corp is a leading provider of innovative products and services in the field of biotechnological research. The company is divided into several business areas, including research and development services, production and distribution of biotechnological products, as well as diagnostic and analysis tools.

Apex Biotechnology izmaksā dividendes 1,30 TWD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Apex Biotechnology vai uzņēmums nedod dividendes.

Apex Biotechnology ISIN ir TW0001733004.

Apex Biotechnology simbols ir 1733.TW.

Pēdējo 12 mēnešu laikā Apex Biotechnology maksāja dividendes 1,40 TWD apmērā. Tas atbilst aptuveni 4,77 % dividendes ražībai. Nākamajos 12 mēnešos Apex Biotechnology plāno maksāt dividendes 1,40 TWD apmērā.

Apex Biotechnology pašreizējā dividendu rentabilitāte ir 4,77 %.

Apex Biotechnology maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos septembris, jūlijs, jūlijs, jūnijs.

Apex Biotechnology pēdējo 21 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 1,40 TWD. Tas atbilst dividendes ražībai 4,77 %.

Apex Biotechnology tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Apex Biotechnology apmērā 1,1 TWD, kas tika izmaksāta 14.06.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 17.05.2024..

Pēdējās dividendes izmaksa notika 14.06.2024..

Gadā 2023, Apex Biotechnology izmaksāja 1,3 TWD dividendes.

Apex Biotechnology dividendes tiek izmaksātas TWD.